Celgene discontinues phase 3 trial for Crohn's disease drug

Celgene said Thursday that it was discontinuing a phase 3 trial for a Crohn's disease drug. "While we are disappointed with the results of REVOLVE, we remain committed to advancing our portfolio of novel medicines for patients suffering from this disease and other inflammatory bowel disorders," Celgene President and Chief Operating Officer Scott Smith said...